Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Karyopharm Therapeut

(NASDAQ: KPTI)
Add to Portfolio
-0.23 (-2.51%)
as of 13:48 EDT

Last 8.93
Change -0.23 (-2.51%)
Open 9.11
Prev. Close 9.16
Today's Range
8.81
9.41
52wk Range
3.92
21.71
Volume 557,412
Avg Volume 1,400,531
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
KPTI -2.51% +54.58% -50.67%
DJIA -1.78% -1.37% +0.36%
S&P 500 -1.94% -1.01% +0.19%

Key Statistics

Annual EPS -3.55
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 576,480
Weighted Alpha -40.47
Standard Deviation -0.94
Profit Margin N/A
Beta 2.40

Growth Rates

YTD -5.14%
1-Year -49.56%
3-Year +32.37%
5-Year -74.56%

Opinion

Sell Hold Buy

Recent Headlines

The Klein Law Firm Reminds Investors of Class Actions

GlobeNewswire via COMTEX - Thu Aug 22, 10:00AM EDT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint yo(full story)
NGHC: 23.69 (-0.14), KPTI: 8.93 (-0.23), FDX: 152.65 (-5.45), CTST: 1.86 (-0.07)

SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB,

GlobeNewswire via COMTEX - Wed Aug 21, 10:50PM EDT
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:(full story)
LB: 17.72 (-1.61), KPTI: 8.93 (-0.23), EGBN: 39.80 (-0.70)

Karyopharm Announces Publication of XPOVIO(TM)

GlobeNewswire via COMTEX - Wed Aug 21, 05:20PM EDT
-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody --(full story)
KPTI: 8.93 (-0.23)

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP

GlobeNewswire via COMTEX - Wed Aug 21, 03:47PM EDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff i(full story)
KPTI: 8.93 (-0.23)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates

GlobeNewswire via COMTEX - Tue Aug 20, 03:49PM EDT
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or (full story)
KPTI: 8.93 (-0.23)